Michael C. Heinrich, M.D.

Head Shot of Michael Heinrich
click here
503 494-6594

Lab Page: Click here


Dr. Heinrich's research includes both preclinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. This includes both genomics research using high-throughput gentoyping to identify oncogenic mutations and testing of new compounds in cellular and biochemical assays. Dr. Heinrich’s laboratory is particularly expert in the analysis of inhibitors of oncogenic receptor tyrosine kinases such as KIT, PDGFRA and FLT3.

Summary of Current Research

Additional special interests

Development of novel tyrosine kinase inhibitors for treatment of human cancers

Selected Publications

"Combination therapy for KIT-mutant mast cells: Targeting constitutive NFAT and KIT activity," Molecular Cancer Therapeutics (Vol: 13, Issue: 12, Page 2840-2851) - 2014

"Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer," Clinical Cancer Research (Vol: 20, Issue: 5, Page 1306-1312) - 2014

"Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)," BMC Cancer (Vol: 14, Issue: 1, ) - 2014

"Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract," Journal of the American Academy of Dermatology (Vol: 71, Issue: 2, Page 229-236) - 2014

"Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial," Journal of Clinical Oncology (Vol: 32, Issue: 15, Page 1563-1570) - 2014


OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


  Email Michael Heinrich

503 494-6594

Memberships & Associations

American Society of Clinical Oncology American Society of Hematology Fellow, American College of Physicians American Association of Cancer Research Alpha Omega Alpha